Board OF DIRECTORS
Dr. Anand Tharmaratnam
Chairman
Dr. Anand Tharmaratnam
Chairman
Anand brings over 20 years of experience in global drug development and the CRO industry. He was previously the president of Asia Pacific at IQVIA. Anand is a medical doctor by training and graduated from the University College London, UK and trained in the anaesthesia.
Mr. Joel Thickins
Board Member
Mr. Joel Thickins
Board Member
Joel is a Partner at TPG Capital and leads the firm’s investment program in the ANZ region as Head of Australia and New Zealand. Joel has previously served on the board of Inghams Group Limited and Accolade Wines Holding Australia Pty Limited.
Before joining TPG, Joel was a director at CPE Capital (formerly known as CHAMP Private Equity) where he was responsible for the company’s activities in the industrial, agricultural services and consumer markets.
Dr. Fred Cohen
Board Member
Dr. Fred Cohen
Board Member
Fred Cohen is a Senior Advisor to TPG and was a partner and co-founder of TPG Biotech. Fred has served on the board of several biotech and pharmaceutical organizations including BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) and CareDx, Inc. (NASDAQ: CDNA)
Mr. Vincent Wong
Board Member
Mr. Vincent Wong
Board Member
Vincent Wong is a Managing Director with TPG Capital and is based in Melbourne, where he works in TPG’s Australian team. Prior to joining TPG in 2011, Vincent served in the corporate advisory division at Goldman Sachs Australia. Vincent graduated from the University of Melbourne with BCommerce and BLaws (Honors).
Ms. Cai Li (蔡俐)
Board Member
Ms. Cai Li (蔡俐)
Board Member
Lydia Cai is a Managing Director with TPG Capital based in Beijing and leads TPG’s healthcare investments in the Greater China area. Prior to joining TPG in 2011, Lydia was an investment associate at HAO Capital, a China-focused early stage private equity fund focusing on growth-stage healthcare investments.
Dr. John Moller
Chief Executive Officer
Dr. John Moller
Chief Executive Officer
John joined Novotech in January 2014 to lead the development of Novotech’s Asia operations. Prior to Novotech John was Managing Director of IVF Australia and Queensland Fertility Group and sat on the Board of Virtus Health Limited. John is a medical doctor by training.
Ms. Elaine Cheung (張綺玲)
Independent non-executive Director
Ms. Elaine Cheung (張綺玲)
Independent non-executive Director
Ms. Cheung is responsible for providing independent advice to the Board. She chairs the Audit Committee and is a member of the Remuneration Committee and the Nomination Committee. Ms. Cheung has more than 30 years of corporate experience in the Asia-Pacific region. In January 1990, Ms. Cheung graduated from San Francisco State University with a bachelor of science degree, majoring in business administration.
Senior Management
Dr. John Moller
Chief Executive Officer
Dr. John Moller
Chief Executive Officer
John joined Novotech in January 2014 to lead the development of Novotech’s Asia operations. Prior to Novotech John was Managing Director of IVF Australia and Queensland Fertility Group and sat on the Board of Virtus Health Limited. John is a medical doctor by training.
Michael stibilj
Chief Operating Officer
Michael stibilj
Chief Operating Officer
Michael has 25 years of experience in the CRO Industry. Prior to joining Novotech in 2017, Michael spent 15 years building and leading operations across Asia for Quintiles/IQVIA, and was senior advisor for TPG Capital.
Rob Speedie
Group Chief Finance Officer
Rob Speedie
Group Chief Finance Officer
Rob was most recently a Managing Director in the TPG Capital Operations Team and lead a number of Strategic Initiatives across TPG’s portfolio, including time as the COO at Greencross. Prior to TPG, Rob was a Partner at PwC where he spent a total of 19 years. His roles at PWC included 10 years as a Transaction Services professional and 10 years in audit services across Australia, Asia and US. He worked in a range of industries including the pharmaceutical sector. Rob acted as Investigating Accountant and Signing Partner on multiple IPOs on the ASX, was a member of PwCs technical accounting issues escalation committee and has significant experience in financial due diligence.
Barry Murphy
Chief Commercial Officer
Barry Murphy
Chief Commercial Officer
Barry joined in July 2014 to lead the growth of Novotech’s Business Development team. Barry started his career as a pharmacist having graduated from the University of Dublin. He has held multiple contract management roles at ICON plc.
Andy Liu
Head of China
Andy Liu
Head of China
Andy worked at Covance, Inc., a global CRO, for more than 10 years in a number of executive positions. Most recently, he was General Manager of Covance's Central Laboratory Service, Asia Pacific, where he led a large multi-functional team of across multiple sites in APAC. Andy holds an MBA from the University of Chicago, an MS in Electrical Engineering from the Rose-Hulman Institute of Technology, and a BS in Electrical Engineering from Tsinghua University.
Veronica Holloway
Chief Legal and Compliance Officer
Veronica Holloway
Chief Legal and Compliance Officer
Veronica joined Novotech in May 2014 to formalise the legal function at Novotech. Prior to Novotech, Veronica held roles as Senior Legal Counsel at EY, Senior Solicitor at Clayton Utz and General Counsel (on secondment) at Novartis Pharmaceuticals Australia Pty Limited. Veronica holds a BA/LLB/LLM.
Angela Edwardson
Chief People Officer
Angela Edwardson
Chief People Officer
Angela joined Novotech in November 2015 and is responsible for Novotech's Human Resources operations including strategy, organisational development, remuneration & reward and workplace health and safety. Angela is passionate about delivering Novotech's vision of being the leading CRO in the Asia Pacific region.